OBJECTIVE: The treatment of agitation in drug- and alcohol-using emergency patients is understudied. METHOD: We performed a retrospective chart review of 105 agitated emergency department patients who received either intramuscular (IM) haloperidol or IM olanzapine, comparing prescribing patterns, level of agitation, response to treatment and side effects in patients positive for drugs or alcohol [D/A(+)] and patients negative for drugs or alcohol [(D/A(-)]. RESULTS: The haloperidol-benzodiazepine combination was the most frequently prescribed treatment in both groups, although alcohol(+) status biased clinicians toward using haloperidol alone. Overall, D/A(+) and D/A(-) patients responded to the initial intervention at similar rates, although D/A(+) patients were rated as more agitated and had more posttreatment sedation than D/A(-) patients. In D/A(+) patients, haloperidol+benzodiazepine and IM olanzapine performed better than haloperidol alone. There were no serious adverse events with any treatment. CONCLUSION: Findings support the generalization of efficacy data from more rarified agitated samples to populations with high rates of substance use and highlight the need for prospective, inclusive, randomized trials comparing the commonly used haloperidol-benzodiazepine combination with newer injectable antipsychotics. Copyright 2010 Elsevier Inc. All rights reserved.
OBJECTIVE: The treatment of agitation in drug- and alcohol-using emergency patients is understudied. METHOD: We performed a retrospective chart review of 105 agitated emergency department patients who received either intramuscular (IM) haloperidol or IM olanzapine, comparing prescribing patterns, level of agitation, response to treatment and side effects in patients positive for drugs or alcohol [D/A(+)] and patients negative for drugs or alcohol [(D/A(-)]. RESULTS: The haloperidol-benzodiazepine combination was the most frequently prescribed treatment in both groups, although alcohol(+) status biased clinicians toward using haloperidol alone. Overall, D/A(+) and D/A(-) patients responded to the initial intervention at similar rates, although D/A(+) patients were rated as more agitated and had more posttreatment sedation than D/A(-) patients. In D/A(+) patients, haloperidol+benzodiazepine and IM olanzapine performed better than haloperidol alone. There were no serious adverse events with any treatment. CONCLUSION: Findings support the generalization of efficacy data from more rarified agitated samples to populations with high rates of substance use and highlight the need for prospective, inclusive, randomized trials comparing the commonly used haloperidol-benzodiazepine combination with newer injectable antipsychotics. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Maryam Ziaei; Ali Massoudifar; Ali Rajabpour-Sanati; Ali-Mohammad Pourbagher-Shahri; Ali Abdolrazaghnejad Journal: Adv J Emerg Med Date: 2018-11-29
Authors: Carlos Roncero; Elena Ros-Cucurull; Raúl Felipe Palma-Álvarez; Alfonso Carlos Abad; Christian Fadeuilhe; Miquel Casas; Lara Grau-López Journal: Clin Neuropharmacol Date: 2017 Nov/Dec Impact factor: 1.592
Authors: Kathryn F Hawk; Rachel L Glick; Arthur R Jey; Sydney Gaylor; Jamie Doucet; Michael P Wilson; John S Rozel Journal: West J Emerg Med Date: 2019-02-19
Authors: Leonardo Baldaçara; Alexandre P Diaz; Verônica Leite; Lucas A Pereira; Roberto M Dos Santos; Vicente de P Gomes Júnior; Elie L B Calfat; Flávia Ismael; Cintia A M Périco; Deisy M Porto; Carlos E K Zacharias; Quirino Cordeiro; Antônio Geraldo da Silva; Teng C Tung Journal: Braz J Psychiatry Date: 2019-03-07 Impact factor: 2.697